Vivani Medical (NASDAQ:VANI) Announces Earnings Results

Vivani Medical (NASDAQ:VANI) issued its quarterly earnings data on Thursday. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01, FiscalAI reports.

Vivani Medical Stock Performance

Shares of NASDAQ:VANI traded up $0.03 during trading on Friday, reaching $1.36. The stock had a trading volume of 26,265 shares, compared to its average volume of 362,114. The business has a fifty day moving average price of $1.29 and a 200-day moving average price of $1.24. The stock has a market cap of $117.72 million, a PE ratio of -3.41 and a beta of 2.35. Vivani Medical has a 1-year low of $0.92 and a 1-year high of $1.92.

Analysts Set New Price Targets

VANI has been the subject of several research analyst reports. Lake Street Capital initiated coverage on Vivani Medical in a research note on Tuesday, June 23rd. They set a “buy” rating and a $4.00 target price for the company. Weiss Ratings raised shares of Vivani Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 7th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $3.75.

Insider Buying and Selling

In other news, Director Gregg Williams acquired 1,587,301 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were bought at an average price of $1.26 per share, for a total transaction of $1,999,999.26. Following the acquisition, the director owned 36,119,086 shares of the company’s stock, valued at approximately $45,510,048.36. This trade represents a 4.60% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 53.30% of the company’s stock.

Institutional Investors Weigh In On Vivani Medical

A number of hedge funds have recently modified their holdings of VANI. Tudor Investment Corp ET AL purchased a new stake in Vivani Medical during the 4th quarter valued at about $1,127,000. Geode Capital Management LLC lifted its stake in Vivani Medical by 29.6% in the 4th quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock worth $568,000 after purchasing an additional 105,398 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Vivani Medical during the 4th quarter worth approximately $174,000. State Street Corp boosted its holdings in shares of Vivani Medical by 12.5% during the 4th quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after purchasing an additional 16,070 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Vivani Medical in the fourth quarter valued at approximately $60,000. 6.78% of the stock is currently owned by institutional investors and hedge funds.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.